Skip to main content

Drugs Made In America Acquisition Corp.

DMAAU
Exchange
Nasdaq
Industry
Blank Checks
SEC CIK
0002028614

No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $122.3K in total; no superinvestor holds it.

Other share classesDMAADMAAR

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Drugs Made In America Acquisition Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Drugs Made In America Acquisition Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Drugs Made In America Acquisition Corp.
NameTitleLast reported holdingLast filingFilings, past year
Stockwell LynnCEO and Exe. Chair of Board4,188,780IndirectFeb 18, 20250
Drugs Made In America Acquisition LLC10% Owner4,188,780Feb 18, 20250
Worman Glenn C.CFO100,000Feb 3, 20250
Prasad Sridhar G.Director100,000Feb 3, 20250
Shulgan Myron W.Director100,000Feb 3, 20250
Do CatherineDirector100,000Feb 3, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 18, 2025 (view filing)Feb 18Same dayDrugs Made In America Acquisition LLC10% OwnerPPurchase+30.0K––+0.7%4.19M afterDuplicate filing
Feb 18, 2025 (view filing)Feb 18Same dayDrugs Made In America Acquisition LLC10% OwnerPPurchase+30.0K–––430.0K afterDerivativeDuplicate filing
Feb 18, 2025 (view filing)Feb 18Same dayStockwell LynnCEO and Exe. Chair of BoardPPurchase+30.0K––+0.7%4.19M after
Feb 18, 2025 (view filing)Feb 18Same dayStockwell LynnCEO and Exe. Chair of BoardPPurchase+30.0K–––430.0K afterDerivative
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerPPurchase+400.0K––+4.1%10.3M after
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerSSale−5.70M––−57.8%4.16M afterDuplicate filing
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerPPurchase+400.0K–––400.0K afterDerivativeDuplicate filing
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBPPurchase+400.0K––New position10.3K after
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBSSale−5.70M––−57.8%4.16M after
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBPPurchase+400.0K–––400.0K afterDerivative